Bewley, Anthony http://orcid.org/0000-0003-1195-0290
Hiribarne, Lauren
Galván, Jordi http://orcid.org/0000-0002-2435-2129
Mburu, Sicily http://orcid.org/0000-0003-1296-4520
Funding for this research was provided by:
Almirall
Article History
Received: 5 February 2024
Accepted: 23 February 2024
First Online: 8 March 2024
Change Date: 30 May 2024
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s13555-024-01168-2
Declarations
:
: Anthony Bewley has served as a consultant to Abbvie, Almirall, Celgene, Galderma, Janssen, Leo Pharma, Lilly, Novartis, Sanofi, and UCB; has participated in advisory boards for Psoriasis Association, Changing Faces, ISG, and NES; has received grants from EADV and travel grants from Janssen, Leo Pharma and Almirall; has participated in guidelines committees of BAD; is working as an editor for the book Practical Psychodermatology, as president for ESDaP and as a chair for APPGOS. Lauren Hiribane was an employee of Wefight during the study. Jordi Galván is an employee of Almirall. Sicily Mburu has no individual conflict of interest and is an employee of IFPA. The authors report no other conflicts of interest in this work.
: This research follows the European Pharmaceutical Market Research Association (EphMRA) code of conduct which outlines the European guidelines on market research and, as such, does not require Clinical Research Ethics Committee or Independent Review Board approval. According to the GDPR guidelines, respondents gave voluntary, informed consent to data collection and use, based on a clear explanation of the purpose of the data collection and the use(s) to which the data will be put.